bpc-157 cycle length for injury Dosing (Common Protocols), πΉ Oral / Subcutaneous, β’ 500 mcg daily, β’ Duration: 6 weeks, πΉ Intramuscular / Peritendinous, β’ 1 mg daily, β’ Duration: 6 weeks, β οΈ Note:, Not approved by FDA or bpc-157 typical cycle length days
Description
Graphical abstract Various mechanism of action of anticancer peptides
Abad E, Sandoz J, Romero G, Zadra I, Urgel-Solas J, Borredat P, et al
One decimal point mistake can mean injecting ten times your intended dose
These include targeted action on the central nervous system, excellent bioavailability, and the rapid onset of systemic effects
